Ovid Therapeutics Inc. (OVID) P/S ratio

P/S ratio today
22.6×

Ovid Therapeutics Inc. (OVID) trades at 22.6× its revenue per share for fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/S ratio was 16.6×. That is 85.8% lower than the 117.0× of fiscal 2024. Figures as of 18 Nov 2026, 02:53 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

P/S ratio today
22.6×
P/S ratio, fiscal 2025
16.6×
Change on fiscal 2024
−85.8%
Highest on record
117.0×fiscal 2024
Lowest on record
1.0×fiscal 2021
Fiscal years on record
52020–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Ovid Therapeutics Inc. P/S ratio, in more detail

Today's figure is 36.2% above the fiscal 2025 year-end.

Across the 5 fiscal year-ends on record (2020–2025), the highest was 117.0× in fiscal 2024 and the lowest 1.0× in fiscal 2021. Today's P/S ratio is higher than at 60% of the 5 fiscal year-ends on record; their median is 16.6×.

History · 5 fiscal years

P/S ratio at each fiscal year-end

The last point is today's figure; the others are fiscal year-ends.

Ovid Therapeutics Inc. P/S ratio, year by year

Ovid Therapeutics Inc. (OVID) P/S ratio by fiscal year
Fiscal yearP/S ratioChangeYear endedShare price at year-endRevenue per share
Today22.6×—$2.22—
202516.6× 85.8% down$1.63$0.10
2024117.0×—$0.93$0.01
2023——$3.22$0.01
202287.2× 8,213.2% up$1.86$0.02
20211.0× 90.2% down$3.21$3.06
202010.7×—$2.31$0.22
2019——$4.15—
2018——$2.42—
2017——$9.87—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.

How to read it

It prices each unit of sales and still works when there is no profit; what counts as high depends on the margin those sales earn.

More on OVID

Ovid Therapeutics Inc., figure by figure

Ovid Therapeutics Inc. (OVID) overview: price, valuation and scorecard

Ovid Therapeutics Inc. P/S ratio: questions and answers

What is Ovid Therapeutics Inc.'s P/S ratio?

Ovid Therapeutics Inc. (OVID) trades at 22.6× its revenue per share for fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/S ratio was 16.6×. That is 85.8% lower than the 117.0× of fiscal 2024.

Is Ovid Therapeutics Inc.'s P/S ratio high or low compared with its own history?

Today's P/S ratio is higher than at 60% of the 5 fiscal year-ends on record; their median is 16.6×.

What are the highest and lowest P/S ratio figures on record for Ovid Therapeutics Inc.?

Across the 5 fiscal year-ends on record (2020–2025), the highest was 117.0× in fiscal 2024 and the lowest 1.0× in fiscal 2021.

How is Ovid Therapeutics Inc.'s P/S ratio calculated?

The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.

Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Ovid Therapeutics Inc. (OVID) P/S ratio”, data as of 18 November 2026. https://funkfolio.com/stock/OVID/ps-ratio

Underlying data: the company's filings with the SEC and Yahoo Finance.